Literature DB >> 30213892

New cancer-fighting cells enter trials.

Mitch Leslie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30213892     DOI： 10.1126/science.361.6407.1056

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  3 in total

1.  Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer.

Authors:  Xiang Ao; Yu Yang; Weiqiang Li; Yan Tan; Wei Guo; Luoquan Ao; Xiao He; Xiaofeng Wu; Jianchuan Xia; Xiang Xu; Jianxin Guo
Journal:  J Immunother       Date:  2019-10       Impact factor: 4.456

Review 2.  The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.

Authors:  Denisa Baci; Annalisa Bosi; Matteo Gallazzi; Manuela Rizzi; Douglas M Noonan; Alessandro Poggi; Antonino Bruno; Lorenzo Mortara
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

3.  Antibody-secreting macrophages generated using CpG-free plasmid eliminate tumor cells through antibody-dependent cellular phagocytosis.

Authors:  Eun Bi Cha; Keun Koo Shin; Jinho Seo; Doo-Byoung Oh
Journal:  BMB Rep       Date:  2020-08       Impact factor: 4.778
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.